A handful of Philly-area companies across industries like biosciences and and information sciences have announced some fundraising in the past two months ranging from a few hundred thousands dollars up to $45 million.

In late May, Palvella Therapeutics, a Wayne-based biopharmaceutical company focused on genetic diseases, announced that it had raised $45 million in Series C funding. In addition, the company said that two key investors — Scott Morenstein, managing director of CAM Capital, and Cory Freedland, principal of Samsara BioCapital — have been nominated to join the Palvella board of directors.

“Palvella was founded on fundamental beliefs that every individual with a rare disease deserves a treatment and that significant value creation occurs upon the introduction of the first approved therapy or a serious rare genetic disease,” said Wes Kaupinen, president and CEO.

READ FULL ARTICLE HERE